At a glance
ClinicalIndex Comparison RecordN/ACompleted· 24 enrolled
Drug / intervention
EPA +2 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Role of EPA and DHA in Fish Oil on Inflammation and Lipoprotein Metabolism
In Brief
A clinical study evaluating EPA, DHA, and 1 other intervention for Metabolic Syndrome. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The objective of this study is to provide critical information regarding both common and distinctive roles of EPA and DHA in systemic inflammation and lipid metabolism.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartMar 2016
Primary CompletionMay 2020
Study CompletionOct 2020
TodayJul 2026
First PostedFeb 1, 2016
Enrollment StartMar 1, 2016
Primary CompletionMay 1, 2020
Study CompletionOct 1, 2020
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 10.4 years ago
Interventions
EPAdietary
10 week supplementation
DHAdietary
10 week supplementation
sunflower oildietary
4-week lead-in